Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-07-20	€0.9100	+2.02%	23,008
26-07-17	€0.8920	-0.89%	1,050
26-07-16	€0.9000	-0.22%	2,162
26-07-15	€0.9020	-0.66%	5,825
26-07-14	€0.9080	+0.89%	1,144

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-20 am EDT			5-day change	1st Jan Change
0.9100 ^EUR	+2.02%		+1.11%	+52.68%

Jun. 11	Triple update for Biosynex
Jun. 10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI

Market Cap	16.44M 18.76M 15.2M 13.98M 26.37M 1.81B 26.8M 182M 71.23M 885M 70.44M 68.9M 3.05B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.63M 79.44M 64.36M 59.2M 112M 7.66B 113M 770M 302M 3.75B 298M 292M 12.91B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

Jun. 11	Triple update for Biosynex
Jun. 10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
May. 25	Paris climbs on hopes of Middle East de-escalation
May. 25	Biosynex announces the divestment of its molecular biology business
May. 24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
May. 07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
Apr. 21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
Apr. 21	Biosynex postpones publication of annual accounts
Mar. 24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
Mar. 24	Observation period extended for Biosynex
Feb. 06	A Biosynex Subsidiary to Receive $1.8 Million Grant
Feb. 06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Jun. 13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
Jun. 11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
Jun. 11	Une bonne grosse purge avant SpaceX
Jun. 11	Triple actualité pour Biosynex
Jun. 11	BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE

1 day	+2.02%
1 week	+1.11%
Current month	+0.89%
1 month	+2.25%
3 months	+7.06%
6 months	+21.98%
Current year	+52.68%

1 week	0.89	0.96
1 month	0.8	1.07
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	11
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/15/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
2/28/22	Larry Abensur	Buy	Chief Executive Officer	254	0.0023%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	+2.02%	+1.11%	-26.61%	-90.89%	18.81M
GUARDANT HEALTH, INC.	-3.62%	-5.04%	+229.56%	+303.14%	20.67B
BIOMÉRIEUX	-1.10%	+1.91%	-39.02%	-23.11%	9.85B
LANTHEUS HOLDINGS, INC.	-1.37%	+1.15%	+48.97%	+25.52%	7B
10X GENOMICS, INC.	-0.58%	+3.84%	+275.87%	-25.85%	5.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+3.43%	+7.18%	-14.36%	-20.83%	5.23B
ANDON HEALTH CO., LTD.	-8.46%	+23.30%	+84.85%	+105.62%	4.9B
CARIS LIFE SCIENCES, INC.	-2.82%	-6.04%	-43.34%	-	4.66B
DIASORIN S.P.A.	+1.27%	+1.04%	-21.12%	-24.84%	4.2B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.21%	+5.98%	-14.81%	-39.11%	2.72B
Average	-0.99%	+3.33%	+48.00%	+23.29%	6.48B
Weighted average by Cap.	-1.89%	+2.23%	+96.34%	+104.21%

	2024	2025
Net sales	101M 115M 93.51M 86.01M 162M 11.13B 165M 1.12B 438M 5.45B 433M 424M 18.76B	95.19M 109M 87.99M 80.93M 153M 10.47B 155M 1.05B 412M 5.12B 408M 399M 17.65B
Net income	-43.33M -49.44M -40.05M -36.84M -69.51M -4.77B -70.62M -479M -188M -2.33B -186M -182M -8.04B	-58.22M -66.43M -53.82M -49.5M -93.39M -6.41B -94.89M -644M -252M -3.13B -249M -244M -10.8B
Net Debt	52.94M 60.39M 48.93M 45M 84.91M 5.82B 86.27M 585M 229M 2.85B 227M 222M 9.82B	53.19M 60.68M 49.17M 45.22M 85.32M 5.85B 86.69M 588M 230M 2.86B 228M 223M 9.86B